| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... The Lancet 383 (9911), 31-39, 2014 | 2385 | 2014 |
| Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial K Shitara, M Özgüroğlu, YJ Bang, M Di Bartolomeo, M Mandalà, MH Ryu, ... The Lancet 392 (10142), 123-133, 2018 | 1157 | 2018 |
| Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma Y Doki, JA Ajani, K Kato, J Xu, L Wyrwicz, S Motoyama, T Ogata, ... New England Journal of Medicine 386 (5), 449-462, 2022 | 609 | 2022 |
| Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis F Pietrantonio, F Petrelli, A Coinu, M Di Bartolomeo, K Borgonovo, ... European journal of cancer 51 (5), 587-594, 2015 | 603 | 2015 |
| Timing of surgery following SARS‐CoV‐2 infection: an international prospective cohort study H Gacaferi, GS Collaborative, COVIDSurg Collaborative Anaesthesia 76 (6), 2021 | 548* | 2021 |
| PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients F Perrone, A Lampis, M Orsenigo, M Di Bartolomeo, A Gevorgyan, M Losa, ... Annals of oncology 20 (1), 84-90, 2009 | 484 | 2009 |
| Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised … C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, ... The lancet oncology 20 (6), 849-861, 2019 | 456 | 2019 |
| Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors E Bajetta, L Ferrari, A Martinetti, L Celio, G Procopio, S Artale, N Zilembo, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1999 | 401 | 1999 |
| Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer F Pietrantonio, R Miceli, A Raimondi, YW Kim, WK Kang, RE Langley, ... Journal of Clinical Oncology 37 (35), 3392-3400, 2019 | 379 | 2019 |
| Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: a study by the Italian Trials in Medical Oncology Group M Di Bartolomeo, E Bajetta, R Buzzoni, L Mariani, C Carnaghi, L Somma, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1996 | 350 | 1996 |
| Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial S Siena, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ... The Lancet Oncology 22 (6), 779-789, 2021 | 284 | 2021 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 229 | 2019 |
| Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group E Bajetta, R Buzzoni, L Mariani, E Beretta, F Bozzetti, G Bordogna, E Aitini, ... Annals of oncology 13 (2), 299-307, 2002 | 202 | 2002 |
| BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ... Annals of oncology 26 (10), 2092-2097, 2015 | 196 | 2015 |
| 5‐Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors E Bajetta, L Rimassa, C Carnaghi, E Seregni, L Ferrari, MD Bartolomeo, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 1998 | 189 | 1998 |
| Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer F Pietrantonio, C Vernieri, G Siravegna, A Mennitto, R Berenato, ... Clinical cancer research 23 (10), 2414-2422, 2017 | 173 | 2017 |
| Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first‐line treatment in metastatic colorectal carcinoma E Bajetta, M Di Bartolomeo, L Mariani, A Cassata, S Artale, S Frustaci, ... Cancer 100 (2), 279-287, 2004 | 162 | 2004 |
| Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours E Bajetta, L Ferrari, G Procopio, L Catena, E Ferrario, A Martinetti, ... Annals of Oncology 13 (4), 614-621, 2002 | 149 | 2002 |
| Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease E Bajetta, A Di Leo, L Biganzoli, L Mariani, F Cappuzzo, M Di Bartolomeo, ... Journal of clinical oncology 14 (9), 2546-2551, 1996 | 149 | 1996 |
| Efficacy of sequential ipilimumab monotherapy versus best supportive care for unresectable locally advanced/metastatic gastric or gastroesophageal junction cancer YJ Bang, JY Cho, YH Kim, JW Kim, M Di Bartolomeo, JA Ajani, ... Clinical Cancer Research 23 (19), 5671-5678, 2017 | 146 | 2017 |
